Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer

Jitsuo Usuda, Yoshihiko Tsunoda, Shuji Ichinose, Taichirou Ishizumi, Keishi Ohtani, Sachio Maehara, Shoutarou Ono, Hidemitsu Tsutsui, Tatsuo Ohira, Tetsuya Okunaka, Kinya Furukawa, Yoshikazu Sugimoto, Harubumi Kato, Norihiko Ikeda

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers. Using human epidermoid carcinoma cells, A431 cells and the BCRP-overexpressing A431/BCRP cells, we examined the effects of BCRP expression on the effect of PDT by cell viability assay in vitro, and investigated the expression of BCRP by immunohistochemical analysis in 81 tumor samples obtained from patients with centrally located early lung cancers. The A431/BCRP cells were more resistant to Photofrin-PDT than A431 cells in vitro, and Fumitremorgin C, a specific inhibitor of BCRP, reversed the resistance. However, there was no significant difference in the antitumor effect of NPe6-PDT between these cells. All of the 81 centrally located early lung cancer lesions were BCRP-positive (2+, 45 lesions; 1+, 30 lesions) and all the patients were male and heavy smokers (>30 pack-years). The expression of BCRP significantly affected the efficacy of Photofrin-PDT in cancer lesions ≥10 mm in diameter (P = 0.04). On the other hand, NPe6-PDT exhibited a strong antitumor effect, regardless of the expression status of BCRP. Photofrin may be a substrate of BCRP and be pumped out from the cells, therefore, BCRP may be a molecular determinant of the outcome of Photofrin-PDT.

Original languageEnglish
Pages (from-to)198-204
Number of pages7
JournalLung Cancer
Volume67
Issue number2
DOIs
Publication statusPublished - 2010 Feb

Fingerprint

Photochemotherapy
Lung Neoplasms
Breast Neoplasms
Dihematoporphyrin Ether
Proteins
Photosensitizing Agents
ATP-Binding Cassette Transporters
Squamous Cell Carcinoma
Neoplasms
Cell Survival

Keywords

  • Breast cancer resistant protein (BCRP)
  • Centrally located early lung cancer
  • Lung cancer
  • Photodynamic therapy (PDT)

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer. / Usuda, Jitsuo; Tsunoda, Yoshihiko; Ichinose, Shuji; Ishizumi, Taichirou; Ohtani, Keishi; Maehara, Sachio; Ono, Shoutarou; Tsutsui, Hidemitsu; Ohira, Tatsuo; Okunaka, Tetsuya; Furukawa, Kinya; Sugimoto, Yoshikazu; Kato, Harubumi; Ikeda, Norihiko.

In: Lung Cancer, Vol. 67, No. 2, 02.2010, p. 198-204.

Research output: Contribution to journalArticle

Usuda, J, Tsunoda, Y, Ichinose, S, Ishizumi, T, Ohtani, K, Maehara, S, Ono, S, Tsutsui, H, Ohira, T, Okunaka, T, Furukawa, K, Sugimoto, Y, Kato, H & Ikeda, N 2010, 'Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer', Lung Cancer, vol. 67, no. 2, pp. 198-204. https://doi.org/10.1016/j.lungcan.2009.04.002
Usuda, Jitsuo ; Tsunoda, Yoshihiko ; Ichinose, Shuji ; Ishizumi, Taichirou ; Ohtani, Keishi ; Maehara, Sachio ; Ono, Shoutarou ; Tsutsui, Hidemitsu ; Ohira, Tatsuo ; Okunaka, Tetsuya ; Furukawa, Kinya ; Sugimoto, Yoshikazu ; Kato, Harubumi ; Ikeda, Norihiko. / Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer. In: Lung Cancer. 2010 ; Vol. 67, No. 2. pp. 198-204.
@article{aa9ad3a312554fcc91f1da671be9f9f3,
title = "Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer",
abstract = "The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers. Using human epidermoid carcinoma cells, A431 cells and the BCRP-overexpressing A431/BCRP cells, we examined the effects of BCRP expression on the effect of PDT by cell viability assay in vitro, and investigated the expression of BCRP by immunohistochemical analysis in 81 tumor samples obtained from patients with centrally located early lung cancers. The A431/BCRP cells were more resistant to Photofrin-PDT than A431 cells in vitro, and Fumitremorgin C, a specific inhibitor of BCRP, reversed the resistance. However, there was no significant difference in the antitumor effect of NPe6-PDT between these cells. All of the 81 centrally located early lung cancer lesions were BCRP-positive (2+, 45 lesions; 1+, 30 lesions) and all the patients were male and heavy smokers (>30 pack-years). The expression of BCRP significantly affected the efficacy of Photofrin-PDT in cancer lesions ≥10 mm in diameter (P = 0.04). On the other hand, NPe6-PDT exhibited a strong antitumor effect, regardless of the expression status of BCRP. Photofrin may be a substrate of BCRP and be pumped out from the cells, therefore, BCRP may be a molecular determinant of the outcome of Photofrin-PDT.",
keywords = "Breast cancer resistant protein (BCRP), Centrally located early lung cancer, Lung cancer, Photodynamic therapy (PDT)",
author = "Jitsuo Usuda and Yoshihiko Tsunoda and Shuji Ichinose and Taichirou Ishizumi and Keishi Ohtani and Sachio Maehara and Shoutarou Ono and Hidemitsu Tsutsui and Tatsuo Ohira and Tetsuya Okunaka and Kinya Furukawa and Yoshikazu Sugimoto and Harubumi Kato and Norihiko Ikeda",
year = "2010",
month = "2",
doi = "10.1016/j.lungcan.2009.04.002",
language = "English",
volume = "67",
pages = "198--204",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer

AU - Usuda, Jitsuo

AU - Tsunoda, Yoshihiko

AU - Ichinose, Shuji

AU - Ishizumi, Taichirou

AU - Ohtani, Keishi

AU - Maehara, Sachio

AU - Ono, Shoutarou

AU - Tsutsui, Hidemitsu

AU - Ohira, Tatsuo

AU - Okunaka, Tetsuya

AU - Furukawa, Kinya

AU - Sugimoto, Yoshikazu

AU - Kato, Harubumi

AU - Ikeda, Norihiko

PY - 2010/2

Y1 - 2010/2

N2 - The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers. Using human epidermoid carcinoma cells, A431 cells and the BCRP-overexpressing A431/BCRP cells, we examined the effects of BCRP expression on the effect of PDT by cell viability assay in vitro, and investigated the expression of BCRP by immunohistochemical analysis in 81 tumor samples obtained from patients with centrally located early lung cancers. The A431/BCRP cells were more resistant to Photofrin-PDT than A431 cells in vitro, and Fumitremorgin C, a specific inhibitor of BCRP, reversed the resistance. However, there was no significant difference in the antitumor effect of NPe6-PDT between these cells. All of the 81 centrally located early lung cancer lesions were BCRP-positive (2+, 45 lesions; 1+, 30 lesions) and all the patients were male and heavy smokers (>30 pack-years). The expression of BCRP significantly affected the efficacy of Photofrin-PDT in cancer lesions ≥10 mm in diameter (P = 0.04). On the other hand, NPe6-PDT exhibited a strong antitumor effect, regardless of the expression status of BCRP. Photofrin may be a substrate of BCRP and be pumped out from the cells, therefore, BCRP may be a molecular determinant of the outcome of Photofrin-PDT.

AB - The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers. Using human epidermoid carcinoma cells, A431 cells and the BCRP-overexpressing A431/BCRP cells, we examined the effects of BCRP expression on the effect of PDT by cell viability assay in vitro, and investigated the expression of BCRP by immunohistochemical analysis in 81 tumor samples obtained from patients with centrally located early lung cancers. The A431/BCRP cells were more resistant to Photofrin-PDT than A431 cells in vitro, and Fumitremorgin C, a specific inhibitor of BCRP, reversed the resistance. However, there was no significant difference in the antitumor effect of NPe6-PDT between these cells. All of the 81 centrally located early lung cancer lesions were BCRP-positive (2+, 45 lesions; 1+, 30 lesions) and all the patients were male and heavy smokers (>30 pack-years). The expression of BCRP significantly affected the efficacy of Photofrin-PDT in cancer lesions ≥10 mm in diameter (P = 0.04). On the other hand, NPe6-PDT exhibited a strong antitumor effect, regardless of the expression status of BCRP. Photofrin may be a substrate of BCRP and be pumped out from the cells, therefore, BCRP may be a molecular determinant of the outcome of Photofrin-PDT.

KW - Breast cancer resistant protein (BCRP)

KW - Centrally located early lung cancer

KW - Lung cancer

KW - Photodynamic therapy (PDT)

UR - http://www.scopus.com/inward/record.url?scp=72449131829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449131829&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2009.04.002

DO - 10.1016/j.lungcan.2009.04.002

M3 - Article

C2 - 19477032

AN - SCOPUS:72449131829

VL - 67

SP - 198

EP - 204

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -